Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's...

Area of Science:

• Oncology
• Biomarker Discovery
• Renal Cell Carcinoma Research

Background:

• Advanced and metastatic renal cell carcinoma (a/mRCC) presents significant treatment challenges.
• Immunotherapy, particularly immune checkpoint inhibitor (ICI)-based therapy, has improved outcomes for a/mRCC patients.
• Accurate prognostic biomarkers are crucial for tailoring treatment strategies and predicting patient response to ICI therapy.

Purpose of the Study:

• To evaluate the utility of the CANLPH score as a predictive biomarker in patients with advanced and metastatic renal cell carcinoma (a/mRCC).
• To validate the prognostic value of the CANLPH score in patients undergoing ICI-based therapy.
• To assess if the CANLPH score can enhance personalized treatment strategies for a/mRCC.

Main Methods:

• A multicenter retrospective study analyzed data from 309 a/mRCC patients treated with ICI-based therapy.
• The CANLPH score, a composite of C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte ratio (NLR), and platelet to hemoglobin ratio (PHR), was assessed for prognostic accuracy.
• Statistical methods included ROC curve analysis, Cox regression, and C-index to evaluate predictive capacity against established factors.

Main Results:

• The CANLPH score significantly stratified survival outcomes for RCC patients on ICI therapy (HR 5.71; P < 0.0001).
• The CANLPH score demonstrated superior predictive potency for cancer-specific survival (CSS) compared to the IMDC score, as indicated by C-index analysis.
• Multivariate analysis identified the CANLPH score (HR, 5.59; P = 0.0007) and Karnofsky performance status as independent prognostic factors for CSS.

Conclusions:

• The CANLPH score is a valuable tool for predicting outcomes in a/mRCC patients receiving ICI-based therapies.
• The score aids in precise prediction of patient prognosis within the current therapeutic landscape.
• Prospective validation studies are recommended due to the retrospective design and single national cohort limitations.